MEDI-4736: A New Drug For Colorectal Carcinoma To Begin Phase II Trial
AstraZeneca has announced early Friday that the company begin a Phase II trial for the MEDI-4736 drug which is an immuno-oncology medicine for colorectal carcinoma. MEDI-4736 is designed to assist the immune system in fighting tumours.
A total of 48 patients with advanced colorectal carcinoma will be enrolled in the Phase II trial according to an update by ClinicalTrials.gov. Of all cancer-related deaths in the country, the third highest number of deaths was contributed by colorectal carcinoma. Apart from colorectal carcinoma, MEDI-4736 has been study for indication in lung cancer along with various head and neck cancer. Briggs Morrison, the Head of medicine development said earlier in July that AstraZeneca might begin tests for another indication in 2014 but did not specify colorectal carcinoma as the indication.
MEDI-4736 belongs to a class of drugs known as anti-PD-L1 therapies. Drugs from this class inhibit a tumour's ability to evade the immune system. From a business point of view, MEDI-4736 is seen as AstraZeneca's new drug hope in an attempt to convince investors to invest in the group which has a future as an independent company. In a race to develop the first drug in the immuno-oncology class, AstraZeneca is ranked No.4 behind rivals including Merck & Co.
Company analyst forecasted that the drug will help sales rise by 75 percent come 2023. This Phase II study is not yet available for recruitment and is being conducted by Memorial Sloan-Kettering Cancer Center in New York in a collaborative effort with the pharmaceutical firm AstraZeneca.
More data on MEDI-4736 in treatment of lung cancer along with various head and neck cancer will be presented by the British drugmaker at an upcoming conference in Madrid, Spain by the end of September.
In recent years, AstraZeneca has become known for Crestor, a cholesterol drug and also Nexium, an ulcer and heartburn pill.
Photo by Wikimedia Commons.
writershibe is a final year medical student with a flair for writing.